Everything You Need to Know About Blincyto in India
What is Blincyto (Blinatumomab)?
Blincyto (blinatumomab) is developed by Amgen. It is an immunotherapy medicine classified as a bispecific T-cell engager (BiTE®). This medicine is intended to help the body's immune system find and destroy certain unhealthy B-cells by connecting CD3-positive T-cells with CD19-positive B-cells.
Unlike conventional chemotherapy, Blincyto works by directing the patient's own immune cells to detect and attack malignant B-cells, making it an important therapeutic option to treat specific forms of Acute Lymphoblastic Leukemia (ALL).
Blincyto is approved in different countries to treat adult and pediatric patients aged one month and older with:
CD19-positive B-cell precursor Acute Lymphoblastic Leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%
Relapsed or refractory CD19-positive B-cell precursor Acute Lymphoblastic Leukemia (ALL)
CD19-positive Philadelphia chromosome-negative B-cell precursor Acute Lymphoblastic Leukemia (ALL) during the consolidation phase of multiphase chemotherapy
As of June 2026, Blincyto is not commercially available in India. Eligible patients may access the medicine through the Named Patient Program (NPP) under the supervision of an experienced hematologist or oncologist.
Why is Blincyto Important in Acute Lymphoblastic Leukemia (ALL)?
Blincyto is an important advancement for treating CD19-positive B-cell precursor Acute Lymphoblastic Leukemia (ALL). This medicine directly attacks rapidly dividing cells. It is formulated to engage the patient's immune system to detect and target leukemia cells.
Due to its targeted mechanism, use of this drug has expanded for patients with minimal residual disease (MRD)-positive ALL, relapsed ALL, and refractory ALL. The formulation of therapies like Blincyto reflects the growing shift toward specialty medicine and immunotherapy in hematologic complications.
Regulatory authorities, including the US FDA and the EMA, have approved Blincyto for specific ALL indications considering the clinical evidence representing its role in treating eligible patients.
Understanding Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia (ALL) is an aggressively progressing cancer of the blood and bone marrow. It affects immature lymphocytes, a type of white blood cell.
As per the information issued by the National Cancer Institute (NCI), ALL has the potential to affect both children and adults. The disease often requires intensive treatment approaches that may include chemotherapy, immunotherapy, targeted therapies, stem cell transplantation, and supportive care.
Patients with relapsed, refractory, or persistent minimal residual form may require specialty treatment, which has increased the importance of advanced therapies such as Blincyto (blinatumomab).
Blincyto for Acute Lymphoblastic Leukemia (ALL):
Minimal Residual Disease (MRD)-Positive ALL:
Blincyto is approved in various countries for certain patients with CD19-positive B-cell precursor ALL who are in complete remission but continue to have detectable minimal residual disease (MRD). MRD positivity may indicate the availability of residual leukemia cells that exist after treatment.
Relapsed or Refractory ALL:
Blincyto is also prescribed for certain patients whose leukemia has come back after previous treatment or has not responded adequately to standard treatments.
Consolidation Phase Treatment:
In specific cases, Blincyto may be used during the consolidation phase of therapy in patients with Philadelphia chromosome-negative BCP ALL.
Patients, caregivers, hematologists, and hospitals often want to know the Blincyto price in India and the process for accessing the medicine.
Blincyto (blinatumomab) is not commercially marketed in India. It can be imported from countries where the medicine is approved and available.
The overall cost of Blincyto in India may vary depending on several factors, including:
Prescribed treatment protocol
Total required treatment cycles
Country of medicine procurement
Cold-chain transportation & shipping charges
Import permits and regulatory documentation
Currency fluctuations and sourcing availability
Indian Pharma Network (IPN) assists patients, hospitals, physicians, and NGOs with access to genuine Blincyto imported from leading global manufacturers and stockists.
For accurate pricing, availability, and import-related assistance, clinicians and patients may contact us directly.
Blincyto Availability in India:
Many patients and doctors search for information regarding Blincyto availability in India. As of now, Blincyto is not approved in India. However, patients may import the medicine through the Named Patient Program (NPP).
Blinatumomab Import in India: Importing Blinatumomab into India generally requires:
Valid physician prescription from the treating doctor
Patient medical documentation
Regulatory compliance procedures
International procurement coordination
Temperature-controlled transportation
Indian Pharma Network (IPN) helps with the coordination of all these processes to help in importing the medicine for eligible patients.
Patients, clinicians, and hospitals looking to buy Blincyto in India may import the medicine through the Named Patient Program (NPP), subject to all applicable regulations and physician prescription.
As Blincyto is not approved in India, procurement generally involves sourcing the medicine from countries where it has received regulatory approval.
Indian Pharma Network (IPN) supports:
Sourcing the medicine from global manufacturers
Named Patient Program (NPP) assistance
Import documentation support
Temperature-controlled logistics
Hospital and patient delivery support
All procurement activities are conducted as per applicable regulations and should be undertaken only under physician supervision.
How to Access Blincyto Through the Named Patient Import: The process generally involves:
Physician evaluation and treatment recommendation
Submission of required patient documentation
Sourcing through leading manufacturers or stockists
Regulatory and import coordination
Shipment and delivery to the treating patient or institution
This pathway helps patients import medicines that are approved in other countries but not commercially available in India.
How Does the Named Patient Program Work for Blincyto?
The Named Patient Program (NPP) is a regulatory pathway that allows eligible patients to access medicines that are approved in other countries but not available in India. Under this framework:
A licensed physician determines medical necessity
Required documentation is prepared
Medicine is sourced from leading manufacturers
Import procedures are done as per regulatory requirements
The medicine is delivered to the patient or treating institution
This pathway is important for patients requiring access to specialized leukemia treatments not yet available in the Indian market.
Where Can Blincyto Be Delivered in India?
Indian Pharma Network (IPN) supports patients, hospitals, NGOs, and clinicians across India through Named Patient Medicine access programs.
Delhi, Gurgaon, Noida, Bangalore, Ghaziabad, Faridabad, Mumbai, Navi Mumbai, Thane, Pune, Nagpur, Nashik, Mysore, Hyderabad, Chennai, Madurai, Coimbatore, Kochi, Trivandrum, Kozhikode, Thrissur, Kolkata, Ahmedabad, Surat, Udaipur, Vadodara, Jaipur, Lucknow, Kanpur, Chandigarh, Mohali, Ludhiana, Amritsar, Bhopal, Indore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, and other cities throughout India.
Why Patients and Hospitals Choose Indian Pharma Network (IPN):
Patients and Healthcare providers trust Indian Pharma Network (IPN) for:
Access to specialty oncology and hematology medicines
International procurement expertise
Named Patient Program (NPP) support
Reliable sourcing from leading manufacturers and approved stockists
Full documentation support
Cold-chain logistics coordination
Delivery support across India
We help facilitate compliant and timely access to specialty therapies for patients with serious medical conditions.
Blincyto (blinatumomab) is a CD19-directed immunotherapy medicine.
Prescribed in specific forms of Acute Lymphoblastic Leukemia (ALL).
Approved in different countries for MRD-positive, relapsed, and refractory ALL.
Not commercially available or approved in India at present.
Patients may access the medicine through the Named Patient Program (NPP).
Indian Pharma Network (IPN) facilitates the import of this therapeutic drug
Cold-chain logistics and full regulatory support may be provided.
Nationwide delivery support is available for patients, clinicians, and hospitals.
Frequently Asked Questions (FAQs):
Is Blincyto available in India?
No, Blincyto is currently not marketed in India. Patients may import the medicine through the Named Patient Program (NPP).
Why is Blincyto not commercially available in India?
As of June 2026, the medicine has not yet been launched for use in India. Access may be facilitated through international procurement pathways.
How can I buy Blincyto in India?
Patients may access Blincyto through the Named Patient Program (NPP), subject to physician prescription and applicable regulations. Indian Pharma Network (IPN) helps facilitate the import of this medicine.
What is the price of Blincyto in India?
The overall cost of Blincyto depends on dosage, treatment duration, sourcing country, freight charges, and regulatory requirements.
What is Blincyto used for?
Blincyto is prescribed for treating patients with CD19-positive B-cell precursor Acute Lymphoblastic Leukemia (ALL).
Can hospitals import Blincyto for patients in India?
Yes. Hospitals and clinicians may facilitate access through compliant Named Patient procedures. Indian Pharma Network (IPN) can help in importing this medicine for patients in India.
Does Blincyto require cold-chain transportation?
Yes. Temperature-controlled logistics may be required depending on product handling specifications.
Can Blincyto be legally imported into India?
Access may be facilitated under applicable Named Patient regulations and physician supervision.
How long does the Blincyto procurement process take?
Timelines may vary depending on sourcing location, documentation requirements, shipping arrangements, and regulatory procedures.
Can Indian Pharma Network support hospital procurement requests?
Yes. We support hospitals, physicians, and NGOs requiring assistance with specialty medicine access through the Named Patient Program.
Is physician prescription mandatory for Blincyto import?
Yes. Physician prescription and certain other supporting medical documentation are important for accessing Blincyto under the Named Patient Import.
Amgen – Blincyto Official Website
U.S. Food and Drug Administration (FDA) – BLINCYTO® (blinatumomab) Prescribing Information
European Medicines Agency (EMA) – Blincyto (blinatumomab)
National Cancer Institute (NCI) – Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)
National Cancer Institute (NCI) – Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
National Institutes of Health (NIH)
MedlinePlus – Blinatumomab Injection
DailyMed – BLINCYTO (blinatumomab) Prescribing Information
American Cancer Society – Acute Lymphocytic Leukemia (ALL)
Leukemia & Lymphoma Society (LLS) – Acute Lymphoblastic Leukemia (ALL)
National Comprehensive Cancer Network (NCCN) – Clinical Practice Guidelines in Oncology
PubMed – Blinatumomab Clinical Studies and Scientific Publications
American Society of Hematology (ASH) – Blood Journal
World Health Organization (WHO) – Cancer Fact Sheets
European Society for Medical Oncology (ESMO) – Hematological Malignancies Resources
Disclaimer: Blincyto (blinatumomab) should only be administered under the supervision of a qualified hematologist or oncologist. Access and import are subject to applicable regulatory requirements, physician prescription, and Named Patient Program regulations.
prguitarman
ellievsbear
amandla
theartofmadeline
turnnoffyourmind
discoholicmusic